Engineering adeno-associated viruses for clinical gene therapy

Nature Reviews Genetics

Volumn 15, Issue 7, 2014, Pages 445-451

  Kotterman, Melissa A ^a,b   Schaffer, David V ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California at Berkeley   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR;

ARTICLE; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; GENOME; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; VIRUS CAPSID; VIRUS INFECTION;

ADENO-ASSOCIATED VIRUS;

CAPSID; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; DIRECTED MOLECULAR EVOLUTION; DNA, VIRAL; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; GENOME, VIRAL; HEMOPHILIA A; HUMANS; METABOLIC DISEASES; MUSCULAR DYSTROPHIES; VIRAL PROTEINS;

EID: 84903587200     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg3742     Document Type: Article

References (73)

1. Boycott, K. M., Vanstone, M. R., Bulman, D. E. & MacKenzie, A. E. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nature Rev. Genet. 14, 681-691 (2013).
2. Stroes, E. S. et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler. Thromb. Vasc. Biol. 28, 2303-2304 (2008).
3. Gaudet, D. et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler. Suppl. 11, 55-60 (2010).
4. Carpentier, A. C. et al. Effect of alipogene tiparvovec (AAV1-LPLS447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metab. 97, 1635-1644 (2012).
5. Hauswirth, W. W. et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 19, 979-990 (2008).
6. Bainbridge, J. W. B. et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239 (2008).
7. Maguire, A. M. et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248 (2008).
8. Maguire, A. M. et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374, 1597-1605 (2009).
9. Jacobson, S. G. et al. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol. 130, 9-24 (2012).
10. Bennett, J. et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci. Transl. Med. 4, 120ra15 (2012).
11. MacLaren, R. E. et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 383, 1129-1137 (2014).
12. Nathwani, A. C. et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365 (2011).
13. Jaski, B. E. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. J. Card. Fail. 15, 171-181 (2009).
14. Jessup, M. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124, 304-313 (2011).
15. DiMattia, M. A. et al. Structural insight into the unique properties of adeno-associated virus serotype 9. J. Virol. 86, 6947-6958 (2012).
16. Govindasamy, L. et al. Structural insights into adeno-associated virus serotype 5. J. Virol. 87, 11187-11199 (2013).
17. Asuri, P. et al. Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol. Ther. 20, 329-338 (2012).
18. Varadi, K. et al. Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800-809 (2012).
19. Dalkara, D. et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl. Med. 5, 189ra76 (2013).
20. Lisowski, L. et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506, 382-386 (2013).
21. Zhong, L. et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl Acad. Sci. USA 105, 7827-7832 (2008).
22. Zhong, L. et al. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381, 194-202 (2008).
23. Martino, A. T. et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224-2233 (2013).
24. Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nature Med. 12, 342-347 (2006).
25. Moskalenko, M. et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 74, 1761-1766 (2000).
26. Wobus, C. E. et al. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74, 9281-9293 (2000).
27. Lochrie, M. A. et al. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80, 821-834 (2006).
28. Mingozzi, F. et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92 (2013).
29. Münch, R. C. et al. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol. Ther. 21, 109-118 (2013).
30. Shen, S. et al. Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J. Biol. Chem. 288, 28814-28823 (2013).
31. Maheshri, N., Koerber, J. T., Kaspar, B. K. & Schaffer, D. V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nature Biotech. 24, 198-204 (2006).
32. Bartel, M. A., Weinstein, J. R. & Schaffer, D. V. Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther. 19, 694-700 (2012).
33. Perabo, L. et al. Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J. Gene Med. 8, 155-162 (2006).
34. Bartel, M. A. et al. Directed evolution of AAV for enhanced evasion of human neutralizing antibodies. Am. Soc. Gene Cell Ther. 15th Annu. Meet. 20, S140 (2012).
35. Excoffon, K. J. D. et al. Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc. Natl Acad. Sci. USA 106, 3865-3870 (2009).
36. Jang, J.-H. et al. An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells. Mol. Ther. 19, 667-675 (2011).
37. Yang, L. et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc. Natl Acad. Sci. USA 106, 3946-3951 (2009).
38. Gray, S. J. et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570-578 (2010).
39. Klimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G. & Schaffer, D. V. A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. PLoS ONE 4, e7467 (2009).
40. Dalkara, D. et al. AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa. Mol. Ther. 19, 1602-1608 (2011).
41. Gaj, T., Gersbach, C. A. & Barbas, C. F. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397-405 (2013).
42. Russell, D. W. & Hirata, R. K. Human gene targeting by viral vectors. Nature Genet. 18, 325-330 (1998).
43. Li, H. et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217-221 (2011).
44. McBride, J. L. et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol. Ther. 19, 2152-2162 (2011).
45. Colella, P. et al. Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors. Gene Ther. 21, 450-456 (2014).
46. Trapani, I. et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol. Med. 6, 194-211 (2014).
47. Zhang, Y. et al. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum. Mol. Genet. 22, 3720-3729 (2013).
48. Boutin, S. et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704-712 (2010).
49. Mingozzi, F. et al. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nature Med. 13, 419-422 (2007).
50. Madsen, D., Cantwell, E. R., O'Brien, T., Johnson, P. A. & Mahon, B. P. Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1. J. Gen. Virol. 90, 2622-2633 (2009).
51. Wu, T.-L. et al. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. Mol. Ther. 22, 42-51 (2014).
52. Faust, S. M. et al. CpG-depleted adeno-associated virus vectors evade immune detection. J. Clin. Invest. 123, 2994-3001 (2013).
53. Dalkara, D. et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol. Ther. 17, 2096-2102 (2009).
54. Summerford, C. & Samulski, R. J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445 (1998).
55. Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80-86 (2010).
56. Ghosh, A. & Duan, D. Expanding adeno-associated viral vector capacity: a tale of two vectors. Biotechnol. Genet. Eng. Rev. 24, 165-177 (2007).
57. Bowles, D., Rabinowitz, J. & Samulski, R. Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production. J. Virol. 77, 423-432 (2003).
58. Grimm, D. et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82, 5887-5911 (2008).
59. Koerber, J. T., Jang, J.-H. & Schaffer, D. V. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol. Ther. 16, 1703-1709 (2008).
60. Li, W. et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 16, 1252-1260 (2008).
61. Koerber, J. T. & Schaffer, D. V. Transposon-based mutagenesis generates diverse adeno-associated viral libraries with novel gene delivery properties. Methods Mol. Biol. 434, 161-170 (2008).
62. Koerber, J. T., Jang, J.-H., Yu, J. H., Kane, R. S. & Schaffer, D. V. Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography. Hum. Gene Ther. 18, 367-378 (2007).
63. Koerber, J. T. et al. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol. Ther. 17, 2088-2095 (2009).
64. Gao, G. et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol. Ther. 13, 77-87 (2006).
65. Bell, P. et al. Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. Hum. Gene Ther. 22, 985-997 (2011).
66. Knipe, D. M. & Howley, P. M. Fields' Virology (Lippincott Williams & Wilkins, 2007).
67. Sonntag, F., Schmidt, K. & Kleinschmidt, J. A. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. USA 107, 10220-10225 (2010).
68. Sonntag, F. et al. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J. Virol. 85, 12686-12697 (2011).
69. Xie, Q. et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl Acad. Sci. USA 99, 10405-10410 (2002).
70. Flotte, T. R. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 11, 805-810 (2004).
71. Flotte, T. R. et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl Acad. Sci. USA 90, 10613-10617 (1993).
72. Schaffer, D. V., Koerber, J. T. & Lim, K. Molecular engineering of viral gene delivery vehicles. Annu. Rev. Biomed. Eng. 10, 169-194 (2008).
73. Wu, Z., Asokan, A. & Samulski, R. J. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 14, 316-327 (2006).